Table 2.
Univariable analysis of TTRs and patient-, tumor-, and treatment-related factors on survival outcomes in the entire cohort
| Parameters | No. of patients | LRRFS | p value | DRFS | p value | DFS | p value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of events | 5-year rate (%) | 95% CI | No. of events | 5-year rate (%) | 95% CI | No. of events | 5-year rate (%) | 95% CI | |||||
| All patients | 989 | 28 | 96.9 | 95.7–98.1 | 86 | 89.3 | 86.8–91.8 | 120 | 85.6 | 82.6–88.3 | |||
| TTR after surgery, days | |||||||||||||
| <147 | 241 | 5 | 98.3 | 96.5–100 | 0.47 | 14 | 92.9 | 88.6–97.2 | 0.01 | 19 | 91.4 | 86.9–91.4 | 0.01 |
| 147–180 | 250 | 6 | 97.1 | 94.7–99.5 | 18 | 91.9 | 87.6–96.2 | 32 | 86 | 80.7–86 | |||
| 181–202 | 245 | 7 | 96.7 | 94.2–99.2 | 29 | 85 | 79.1–90.9 | 35 | 82.4 | 76.3–82.4 | |||
| >202 | 253 | 10 | 95.4 | 92.5–98.3 | 25 | 87.4 | 81.9–92.9 | 34 | 83.2 | 77.1–83.2 | |||
| TTR after CT, weeks | |||||||||||||
| <4 | 415 | 11 | 96.8 | 94.8–98.8 | 0.95 | 42 | 87.4 | 83.3–91.5 | 0.22 | 60 | 82.2 | 77.5–82.2 | 0.08 |
| 4–8 | 314 | 10 | 96.9 | 92.6–100 | 24 | 90.3 | 85.8–94.8 | 35 | 87.5 | 82.8–87.5 | |||
| 8–12 | 84 | 2 | 96.9 | 94.7–98.7 | 6 | 90.6 | 82.4–98.8 | 7 | 89.5 | 81.3–89.5 | |||
| >12 | 45 | 1 | 97.7 | 93.2–100 | 7 | 85.2 | 74.2–96.2 | 10 | 78.6 | 66.1–78.6 | |||
| Age, years | |||||||||||||
| ≤40 | 163 | 5 | 96.3 | 93.2–99.4 | 0.86 | 11 | 92.3 | 86.6–98 | 0.33 | 22 | 83.8 | 76.4–91.2 | 0.48 |
| >40 | 826 | 23 | 97 | 95.6–98.4 | 75 | 88.7 | 86–91.4 | 98 | 86 | 83.1–88.9 | |||
| Comorbidity | |||||||||||||
| No | 800 | 23 | 96.8 | 95.4–98.2 | 0.91 | 63 | 90.4 | 87.7–93.1 | 0.04 | 88 | 87.1 | 84.2–90 | 0.02 |
| Yes | 189 | 5 | 97.1 | 94.6–99.6 | 23 | 84.4 | 77.7–91.1 | 32 | 79.6 | 72.3–86.9 | |||
| T stage | |||||||||||||
| T1 | 511 | 11 | 97.8 | 96.4–99.2 | 0.30 | 24 | 94 | 91.3–96.7 | <0.01 | 40 | 91 | 87.9–94.1 | <0.01 |
| T2 | 427 | 16 | 95.5 | 93.1–97.9 | 57 | 83.3 | 78.6–88 | 74 | 78.7 | 73.6–83.8 | |||
| T3–4 | 40 | 1 | 97.4 | 92.5–100 | 5 | 86.6 | 75.6–97.6 | 6 | 84.5 | 72.9–96.1 | |||
| N stage | |||||||||||||
| N0 | 339 | 6 | 98.0 | 96.4–99.6 | 0.03 | 18 | 92.5 | 88.8–96.2 | <0.01 | 27 | 89.7 | 85.8–93.6 | <0.01 |
| N1 | 362 | 8 | 97.8 | 96.2–99.4 | 25 | 92.6 | 88.9–96.3 | 35 | 90 | 85.9–94.1 | |||
| N2 | 174 | 7 | 94.8 | 90.7–98.9 | 22 | 84.3 | 77.2–91.4 | 28 | 78.6 | 70.6–86.6 | |||
| N3 | 111 | 7 | 93.2 | 88.3–98.1 | 20 | 77.7 | 68.5–86.9 | 29 | 72 | 62.8–81.2 | |||
| Nuclear grade | |||||||||||||
| I–II | 426 | 9 | 98.0 | 96.6–99.4 | 0.13 | 27 | 93.6 | 90.7–96.5 | 0.01 | 41 | 89.8 | 86.3–93.3 | 0.01 |
| III | 453 | 16 | 95.5 | 93.1–97.9 | 45 | 86.3 | 82.2–90.4 | 64 | 81.8 | 77.3–86.3 | |||
| HR status | |||||||||||||
| Negative | 304 | 13 | 95.3 | 92.8–97.8 | 0.045 | 27 | 89.3 | 85–93.6 | 0.67 | 42 | 83.6 | 78.7–88.5 | 0.17 |
| Positive | 685 | 15 | 97.6 | 96.2–99 | 59 | 89.3 | 86.2–92.4 | 78 | 86.6 | 83.3–89.9 | |||
| Breast cancer subtypes | |||||||||||||
| HR-positive | 590 | 13 | 97.6 | 96.2–99.0 | 0.16 | 55 | 88.3 | 84.8–91.8 | 0.68 | 75 | 85.1 | 81.4–88.8 | 0.30 |
| TNBC | 196 | 9 | 95.7 | 92.8–98.6 | 17 | 89.8 | 84.7–94.9 | 32 | 82.1 | 75.8–88.4 | |||
| HER2-positive | 203 | 6 | 96.7 | 94.0–99.4 | 14 | 91.6 | 87.3–95.9 | 23 | 87.9 | 83–92.8 | |||
| Type of primary surgery | |||||||||||||
| Mastectomy | 539 | 19 | 96.2 | 94.4–98 | 0.15 | 63 | 86.1 | 82.4–89.8 | <0.01 | 86 | 81.7 | 77.6–85.8 | <0.01 |
| BCS | 450 | 9 | 97.7 | 96.1–99.3 | 23 | 93.4 | 90.5–96.3 | 34 | 91 | 87.7–94.3 | |||
| Parameters | BCSS | p value | OS | p value | ||||
|---|---|---|---|---|---|---|---|---|
| No. of events | 5-year rate (%) | 95% CI | No. of events | 5-year rate (%) | 95% CI | |||
| All patients | 55 | 94 | 92–95.9 | 61 | 93.5 | 91.5–95.5 | ||
| TTR after surgery, days | ||||||||
| <147 | 12 | 94.4 | 90.5–98.3 | 0.11 | 14 | 94 | 90.1–97.9 | 0.31 |
| 147–180 | 12 | 95.9 | 93.2–98.6 | 15 | 94.7 | 91.6–97.8 | ||
| 181–202 | 12 | 95.2 | 91.3–99.1 | 13 | 94.8 | 90.7–98.9 | ||
| >202 | 19 | 90.5 | 86.2–94.8 | 19 | 90.5 | 86.2–94.8 | ||
| TTR after CT, weeks | ||||||||
| <4 | 23 | 93.7 | 90.8–96.6 | 0.02 | 26 | 93 | 89.9–96.1 | 0.048 |
| 4–8 | 16 | 94.8 | 92.1–97.5 | 18 | 94.2 | 91.3–97.1 | ||
| 8–12 | 4 | 98.5 | 95.6–100 | 4 | 98.5 | 95.6–100 | ||
| >12 | 7 | 85.1 | 73.9–96.3 | 7 | 85.1 | 73.9–96.3 | ||
| Age, years | ||||||||
| ≤40 | 3 | 98.4 | 96.2–100 | 0.02 | 3 | 98.4 | 96.2–100 | 0.01 |
| >40 | 52 | 93.1 | 90.9–95.3 | 58 | 92.5 | 90.1–94.9 | ||
| Comorbidity | ||||||||
| No | 37 | 95 | 93–97 | 0.01 | 42 | 94.5 | 92.5–96.5 | 0.02 |
| Yes | 18 | 89.6 | 84.3–94.9 | 19 | 89.1 | 83.8–94.4 | ||
| T stage | ||||||||
| T1 | 18 | 96.6 | 94.8–98.4 | <0.01 | 22 | 96.0 | 94–98 | 0.04 |
| T2 | 33 | 91.1 | 87.4–94.8 | 35 | 90.7 | 87–94.4 | ||
| T3–4 | 4 | 87.8 | 76.2–99.4 | 4 | 87.8 | 76.2–99.4 | ||
| N stage | ||||||||
| N0 | 11 | 95.2 | 92.1–98.3 | <0.01 | 14 | 94.6 | 91.3–97.9 | <0.01 |
| N1 | 14 | 97.8 | 96.2–99.4 | 15 | 97.5 | 95.7–99.3 | ||
| N2 | 10 | 92.8 | 88.1–97.5 | 10 | 92.8 | 88.1–97.5 | ||
| N3 | 19 | 82.7 | 74.3–91.1 | 21 | 81.1 | 72.5–89.7 | ||
| Nuclear grade | ||||||||
| I–II | 16 | 96.6 | 94.6–98.6 | 0.02 | 19 | 95.9 | 93.7–98.1 | 0.04 |
| III | 29 | 92.8 | 89.7–95.9 | 31 | 92.3 | 89.2–95.4 | ||
| HR status | ||||||||
| Negative | 24 | 90.5 | 86.4–94.6 | 0.01 | 27 | 89.5 | 85.2–93.8 | 0.01 |
| Positive | 31 | 95.5 | 93.5–97.5 | 34 | 95.2 | 93.2–97.2 | ||
| Breast cancer subtypes | ||||||||
| HR-positive | 29 | 95 | 92.6–97.4 | 0.03 | 32 | 94.7 | 92.3–97.1 | <0.01 |
| TNBC | 18 | 89.7 | 84.6–94.8 | 21 | 88.3 | 83.0–93.6 | ||
| HER2-positive | 8 | 95.2 | 91.5–98.9 | 8 | 95.2 | 91.5–98.9 | ||
| Type of primary surgery | ||||||||
| Mastectomy | 41 | 92.1 | 89.4–94.8 | 0.01 | 43 | 91.8 | 89.1–94.5 | 0.03 |
| BCS | 14 | 96.3 | 93.8–98.8 | 18 | 95.6 | 92.9–98.3 | ||
TNBC triple-negative breast cancer, LRRFS locoregional recurrence-free survival, DRFS distant recurrence-free survival, DFS disease-free survival, BCSS breast cancer-specific survival, OS overall survival, CI confidence interval, TTR time to initiation of adjuvant radiotherapy, CT chemotherapy, HR hormone receptor, BCS breast-conserving surgery